Cargando…

Prediction of Clinical Outcome in Endometrial Carcinoma Based on a 3-lncRNA Signature

Endometrial carcinoma (EC) is one of the common gynecological cancers with increasing incidence and revived mortality recently. Given the heterogeneity of tumors and the complexity of lncRNAs, a panel of lncRNA biomarkers might be more precise and stable for prognosis. In the present study, we devel...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Hongmei, Jiang, Fei, Deng, Lifeng, Wang, Juan, Wang, Ping, Ji, Mintao, Li, Jie, Shi, Weiqiang, Pei, Yufang, Li, Jiafu, Zhang, Yue, Zhang, Zengli, Chen, Youguo, Li, Bingyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844015/
https://www.ncbi.nlm.nih.gov/pubmed/35178403
http://dx.doi.org/10.3389/fcell.2021.814456
_version_ 1784651392587137024
author Ding, Hongmei
Jiang, Fei
Deng, Lifeng
Wang, Juan
Wang, Ping
Ji, Mintao
Li, Jie
Shi, Weiqiang
Pei, Yufang
Li, Jiafu
Zhang, Yue
Zhang, Zengli
Chen, Youguo
Li, Bingyan
author_facet Ding, Hongmei
Jiang, Fei
Deng, Lifeng
Wang, Juan
Wang, Ping
Ji, Mintao
Li, Jie
Shi, Weiqiang
Pei, Yufang
Li, Jiafu
Zhang, Yue
Zhang, Zengli
Chen, Youguo
Li, Bingyan
author_sort Ding, Hongmei
collection PubMed
description Endometrial carcinoma (EC) is one of the common gynecological cancers with increasing incidence and revived mortality recently. Given the heterogeneity of tumors and the complexity of lncRNAs, a panel of lncRNA biomarkers might be more precise and stable for prognosis. In the present study, we developed a new lncRNA model to predict the prognosis of patients with EC. EC-associated differentially expressed long noncoding RNAs (lncRNAs) were identified from The Cancer Genome Atlas (TCGA). Univariate COX regression and least absolute shrinkage and selection operator (LASSO) model were selected to find the 8-independent prognostic lncRNAs of EC patient. Furthermore, the risk score of the 3-lncRNA signature for overall survival (OS) was identified as CTD-2377D24.6 expression × 0.206 + RP4-616B8.5 × 0.341 + RP11-389G6.3 × 0.343 by multivariate Cox regression analysis. According to the median cutoff value of this prognostic signature, the EC samples were divided into two groups, high-risk set (3-lncRNAs at high levels) and low-risk set (3-lncRNAs at low levels), and the Kaplan–Meier survival curves demonstrated that the low-risk set had a higher survival rate than the high-risk set. In addition, the 3-lncRNA signature was closely linked with histological subtype (p = 0.0001), advanced clinical stage (p = 0.011), and clinical grade (p < 0.0001) in EC patients. Our clinical samples also confirmed that RP4-616B8.5, RP11-389G6.3, and CTD-2377D24.6 levels were increased in tumor tissues by qRT-PCR and in situ hybridization. Intriguingly, the p-value of combined 3-lncRNAs was lower than that of each lncRNA, indicating that the 3-lncRNA signature also showed higher performance in EC tissue than paracancerous. Functional analysis revealed that cortactin might be involved in the mechanism of 3-lncRNA signatures. These findings provide the first hint that a panel of lncRNAs may play a critical role in the initiation and metastasis of EC, indicating a new signature for early diagnosis and therapeutic strategy of uterine corpus endometrial carcinoma.
format Online
Article
Text
id pubmed-8844015
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88440152022-02-16 Prediction of Clinical Outcome in Endometrial Carcinoma Based on a 3-lncRNA Signature Ding, Hongmei Jiang, Fei Deng, Lifeng Wang, Juan Wang, Ping Ji, Mintao Li, Jie Shi, Weiqiang Pei, Yufang Li, Jiafu Zhang, Yue Zhang, Zengli Chen, Youguo Li, Bingyan Front Cell Dev Biol Cell and Developmental Biology Endometrial carcinoma (EC) is one of the common gynecological cancers with increasing incidence and revived mortality recently. Given the heterogeneity of tumors and the complexity of lncRNAs, a panel of lncRNA biomarkers might be more precise and stable for prognosis. In the present study, we developed a new lncRNA model to predict the prognosis of patients with EC. EC-associated differentially expressed long noncoding RNAs (lncRNAs) were identified from The Cancer Genome Atlas (TCGA). Univariate COX regression and least absolute shrinkage and selection operator (LASSO) model were selected to find the 8-independent prognostic lncRNAs of EC patient. Furthermore, the risk score of the 3-lncRNA signature for overall survival (OS) was identified as CTD-2377D24.6 expression × 0.206 + RP4-616B8.5 × 0.341 + RP11-389G6.3 × 0.343 by multivariate Cox regression analysis. According to the median cutoff value of this prognostic signature, the EC samples were divided into two groups, high-risk set (3-lncRNAs at high levels) and low-risk set (3-lncRNAs at low levels), and the Kaplan–Meier survival curves demonstrated that the low-risk set had a higher survival rate than the high-risk set. In addition, the 3-lncRNA signature was closely linked with histological subtype (p = 0.0001), advanced clinical stage (p = 0.011), and clinical grade (p < 0.0001) in EC patients. Our clinical samples also confirmed that RP4-616B8.5, RP11-389G6.3, and CTD-2377D24.6 levels were increased in tumor tissues by qRT-PCR and in situ hybridization. Intriguingly, the p-value of combined 3-lncRNAs was lower than that of each lncRNA, indicating that the 3-lncRNA signature also showed higher performance in EC tissue than paracancerous. Functional analysis revealed that cortactin might be involved in the mechanism of 3-lncRNA signatures. These findings provide the first hint that a panel of lncRNAs may play a critical role in the initiation and metastasis of EC, indicating a new signature for early diagnosis and therapeutic strategy of uterine corpus endometrial carcinoma. Frontiers Media S.A. 2022-02-01 /pmc/articles/PMC8844015/ /pubmed/35178403 http://dx.doi.org/10.3389/fcell.2021.814456 Text en Copyright © 2022 Ding, Jiang, Deng, Wang, Wang, Ji, Li, Shi, Pei, Li, Zhang, Zhang, Chen and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Ding, Hongmei
Jiang, Fei
Deng, Lifeng
Wang, Juan
Wang, Ping
Ji, Mintao
Li, Jie
Shi, Weiqiang
Pei, Yufang
Li, Jiafu
Zhang, Yue
Zhang, Zengli
Chen, Youguo
Li, Bingyan
Prediction of Clinical Outcome in Endometrial Carcinoma Based on a 3-lncRNA Signature
title Prediction of Clinical Outcome in Endometrial Carcinoma Based on a 3-lncRNA Signature
title_full Prediction of Clinical Outcome in Endometrial Carcinoma Based on a 3-lncRNA Signature
title_fullStr Prediction of Clinical Outcome in Endometrial Carcinoma Based on a 3-lncRNA Signature
title_full_unstemmed Prediction of Clinical Outcome in Endometrial Carcinoma Based on a 3-lncRNA Signature
title_short Prediction of Clinical Outcome in Endometrial Carcinoma Based on a 3-lncRNA Signature
title_sort prediction of clinical outcome in endometrial carcinoma based on a 3-lncrna signature
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844015/
https://www.ncbi.nlm.nih.gov/pubmed/35178403
http://dx.doi.org/10.3389/fcell.2021.814456
work_keys_str_mv AT dinghongmei predictionofclinicaloutcomeinendometrialcarcinomabasedona3lncrnasignature
AT jiangfei predictionofclinicaloutcomeinendometrialcarcinomabasedona3lncrnasignature
AT denglifeng predictionofclinicaloutcomeinendometrialcarcinomabasedona3lncrnasignature
AT wangjuan predictionofclinicaloutcomeinendometrialcarcinomabasedona3lncrnasignature
AT wangping predictionofclinicaloutcomeinendometrialcarcinomabasedona3lncrnasignature
AT jimintao predictionofclinicaloutcomeinendometrialcarcinomabasedona3lncrnasignature
AT lijie predictionofclinicaloutcomeinendometrialcarcinomabasedona3lncrnasignature
AT shiweiqiang predictionofclinicaloutcomeinendometrialcarcinomabasedona3lncrnasignature
AT peiyufang predictionofclinicaloutcomeinendometrialcarcinomabasedona3lncrnasignature
AT lijiafu predictionofclinicaloutcomeinendometrialcarcinomabasedona3lncrnasignature
AT zhangyue predictionofclinicaloutcomeinendometrialcarcinomabasedona3lncrnasignature
AT zhangzengli predictionofclinicaloutcomeinendometrialcarcinomabasedona3lncrnasignature
AT chenyouguo predictionofclinicaloutcomeinendometrialcarcinomabasedona3lncrnasignature
AT libingyan predictionofclinicaloutcomeinendometrialcarcinomabasedona3lncrnasignature